Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Almonertinib vs Osimertinib in EGFR+ NSCLC with Brain Metastases
NCT04870190Phase 3Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Intracranial Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04870190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870190.